Custom cancer vaccine trial aims to stop prostate Cancer's return
NCT ID NCT05010200
Summary
This early-stage study is testing the safety of a personalized vaccine designed to teach the immune system to attack a man's specific prostate cancer. It is for men with aggressive prostate cancer who have had their prostate removed but still have a high risk of the cancer coming back. The vaccine is made from the unique genetic markers of each patient's tumor and is given with an immune-boosting drug to try to prevent recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.